首页> 外文期刊>BMC Pulmonary Medicine >The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan
【24h】

The relationship between high-dose corticosteroid treatment and mortality in acute respiratory distress syndrome: a retrospective and observational study using a nationwide administrative database in Japan

机译:大剂量皮质类固醇激素治疗与急性呼吸窘迫综合征死亡率之间的关系:使用日本全国性行政数据库进行的回顾性研究

获取原文
           

摘要

In the 1980s, randomized-controlled trials showed that high-dose corticosteroid treatment did not improve the mortality of acute respiratory distress syndrome (ARDS). However, while the diagnostic criteria for ARDS have since changed, and supportive therapies have been improved, no randomized-controlled trials have revisited this issue since 1987; thus, the effect of high-dose corticosteroid treatment may be different in this era. We evaluated the effect of high-dose corticosteroid treatment in patients with ARDS using a nationwide administrative database in Japan in a retrospective and observational study. This study was performed with a large population using the 2012 Japanese nationwide administrative database (diagnostic procedure combination). We evaluated the mortality of ARDS patients receiving or not receiving high-dose corticosteroid treatment within 7?days of hospital admission. We employed propensity score weighting with a Cox proportional hazards model in order to minimize the bias associated with the retrospective collection of data on baseline characteristics and compared the mortality between the high-dose and non-high-dose corticosteroid groups. Data from 2707 patients were used; 927 patients were treated with high-dose corticosteroid and 1780 patients were treated without high-dose corticosteroid, within 7?days of admission. After adjusting for confounds, mortality rates within 3?months were significantly higher in the high-dose corticosteroid group compared to the non-high-dose corticosteroid group (weighted hazard ratio: 1.59; 95% CI: 1.37-1.84; P?< 0.001). Our results suggest that high-dose corticosteroid treatment does not improve the prognosis of patients with ARDS, even in this era. However, this study has limitations owing to its retrospective and observational design.
机译:在1980年代,随机对照试验表明,大剂量皮质类固醇激素治疗不能改善急性呼吸窘迫综合征(ARDS)的死亡率。然而,尽管自此改变了ARDS的诊断标准,并改善了支持疗法,但自1987年以来,尚无任何随机对照试验重新探讨该问题。因此,在这个时代,大剂量皮质类固醇激素的治疗​​效果可能会有所不同。在回顾性和观察性研究中,我们使用日本全国性管理数据库评估了大剂量皮质类固醇激素治疗对ARDS患者的疗效。这项研究使用2012年日本全国行政数据库(诊断程序组合)在大量人群中进行。我们评估了入院后7天内接受或未接受大剂量皮质类固醇治疗的ARDS患者的死亡率。我们使用倾向评分加权和Cox比例风险模型,以最大程度地减少与回顾性收集基线特征数据相关的偏差,并比较高剂量和非高剂量皮质类固醇组的死亡率。使用来自2707名患者的数据;在入院后7天之内,有927例接受大剂量皮质类固醇治疗,有1780例没有接受大剂量皮质类固醇治疗。调整混杂因素后,高剂量皮质类固醇组的3个月内死亡率显着高于非高剂量皮质类固醇组(加权危险比:1.59; 95%CI:1.37-1.84; P <0.001 )。我们的结果表明,即使在这个时代,大剂量皮质类固醇激素治疗也不能改善ARDS患者的预后。然而,由于其回顾性和观察性设计,该研究存在局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号